Phase I/II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of CD8 Enriched Tumor Infiltrating Lymphocytes Genetically Engineered to Express IL-12.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Tavokinogene telseplasmid (Primary) ; Cyclophosphamide; Fludarabine
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 26 Nov 2015 Biomarkers information updated
- 31 Oct 2013 Planned end date changed from 1 Oct 2013 to 1 Oct 2014 as reported by ClinicalTrials.gov.
- 08 Aug 2013 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.